FDA Insights on GMP Violations & AAHP Homeopathic 483 Study Webinar
FDA Insights on GMP Violations & AAHP Homeopathic 483 Study Webinar
Hear directly from FDA at AAHP’s upcoming webinar. Learn from the agency about compliance trends and inspection insights relevant to homeopathic drug manufacturers through AAHP’s ongoing Compliance Through Education program.
About the Program
GMP compliance-related issues remain the leading cause of FDA warning letters across the homeopathic industry. This webinar brings together regulatory perspective and industry expertise to help manufacturers better understand what FDA is looking for during inspections.
Attendees will gain practical insight into recent compliance actions, as well as a deeper understanding of common compliance gaps observed during facility inspections so companies can better prepare for their next inspection.
Event Information
- Virtual via Zoom
- Wednesday, June 10, 2026
- 12:00 PM - 1:30 ET
- Complimentary to members and non-members
Featured Speakers
Francis Godwin, MBA
Director, Office of Manufacturing Quality (OMQ), Office of Compliance, CDER, FDA Francis Godwin will provide an FDA perspective on recentcompliance actions affecting homeopathic drug products, drawing on his extensive experience overseeing domestic and international CGMP compliance activities.
Eric L. Foxman, RPh (Ret.)
Senior Scientist, HPUS; Former AAHP Secretary and Board Member
With more than four decades of experience in the homeopathic industry, Eric Foxman will present a retrospective review of FDA 483 observations of inspections of homeopathic manufacturing sites, highlighting key trends and lessons to be learned.
What You Will Learn
- Overview and examples of inspection compliance.
- FDA’s hot topics which result in warning letters.
- What inspection observations are made most often across the board.
- What initial areas companies can focus on, which will make a positive difference in the 483 list of observations.
- An overview of the breadth of observations for a second pass at increasing compliance before the next inspection occurs.
Who Should Attend
This seminar is a must-attend for domestic and foreign firms who manufacture, label, pack, or hold homeopathic drug products for sale in the United States.
- Quality Staff
- Legal & Regulatory Staff
- Product Leads
- Product R&D Staff
- Company Leaders (President/CEO)
- And those similarly responsible at your contract manufacturer
Please contact Association Manager Hayley Sotolotto via email at info@theaahp.org or by voice message at (413) 515-8133 with questions or concerns.